SCHEDULING STATUS

S2

1. NAME OF THE MEDICINE

BAYER ASPIRIN CARDIO 100
100 mg Enteric Coated Tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 100 mg acetylsalicylic acid
Sugar free
For a full list of excipients, refer to section 6.1.

3. PHARMACEUTICAL FORM

Enteric coated tablets
White, round, coated tablets.

4. CLINICAL PARTICULARS

4.1 Therapeutic Indication

BAYER ASPIRIN CARDIO 100 is indicated in adults for the following cardiovascular uses:
- To reduce the risk of myocardial infarction in patients with unstable angina or in patients who have had a previous myocardial infarction.
- To reduce the risk of recurrent transient ischaemic attacks or stroke in patients who have had transient ischaemia of the brain due to fibrin platelet emboli.
- To reduce the risk of graft occlusion following aortocoronary by-pass surgery.
- For reducing the risk of myocardial ischaemic events in people at increased cardiovascular risk.

4.2 Posology and method of administration

Posology

The usual dose is 100 mg daily.

For reducing the risk of myocardial ischaemic events in people with increased cardiovascular risk: 100 mg to be taken every day preferably at the same time each day according to the individual needs of the patient, as determined by the medical practitioner.
Method of administration
For oral use

The tablets should preferably be taken at least 30 minutes before meals, with plenty of water. They should not be crushed, broken, or chewed to ensure a release in the alkaline milieu of the intestine and to not destroy the protective effect of the enteric coating.

Special populations

Paediatric patients
The safety and efficacy of BAYER ASPIRIN CARDIO 100 in children below 18 years of age has not been established. No data are available. Therefore, BAYER ASPIRIN CARDIO 100 is not recommended for use in paediatric patients, below 18 years.

Patients with hepatic impairment
BAYER ASPIRIN CARDIO 100 is contraindicated in patients with severe hepatic failure (see section 4.3). BAYER ASPIRIN CARDIO 100 should be used with particular caution in patients with impaired hepatic function (see section 4.4).

Patients with renal impairment
BAYER ASPIRIN CARDIO 100 is contraindicated in patients with severe renal failure (see section 4.3). BAYER ASPIRIN CARDIO 100 should be used with particular caution in patients with impaired renal function since acetylsalicylic acid may further increase the risk of renal impairment and acute renal failure (see section 4.4).

4.3 Contraindications

- Hypersensitivity to acetylsalicylic acid, to other salicylates, or to any other components of BAYER ASPIRIN CARDIO 100 (see section 6.1)
- A history of asthma induced by the administration of salicylates or substances with a similar action, notably non-steroidal anti-inflammatory medicines.
- History of gastrointestinal perforation, ulceration or bleeding (peptic ulcer bleedings-PUBs) related to previous NSAIDs including BAYER ASPIRIN CARDIO 100
- Acute gastrointestinal ulcers
- Haemorrhagic diathesis
- Severe renal impairment (eGFR < 30 mL/minute)
- Severe hepatic impairment (Child-Pugh C)
- Severe cardiac failure (NYHA grade III or IV)
- Combination with methotrexate at doses of 15 mg/week or more (see section 4.5)
- Last trimester of pregnancy (see section 4.6)

4.4 Special warnings and precautions for use

BAYER ASPIRIN CARDIO 100 should be used with particular caution in the following cases:

- hypersensitivity to analgesics/ anti-inflammatory agents/ antirheumatic medicinal products and in the presence of other allergies.
- history of gastro-intestinal ulcers including chronic or recurrent ulcer disease or history of gastrointestinal bleedings
- The elderly have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation (PUBs) which may be fatal (see section 4.8)
- The risk of gastrointestinal bleeding or perforation (PUBs) is higher with increasing doses of BAYER ASPIRIN CARDIO 100, in patients with a history of ulcers and the elderly.
- When gastrointestinal bleeding or ulceration occurs in patients receiving BAYER ASPIRIN CARDIO 100, treatment with BAYER ASPIRIN CARDIO 100 should be stopped.
- BAYER ASPIRIN CARDIO 100 should be given with caution to patients with a history of gastrointestinal disease (e.g. ulcerative colitis, Crohn's disease, hiatus hernia, gastro-oesophageal reflux disease, angiodysplasia) as the condition may be exacerbated.
  - with concomitant treatment with anticoagulants (see section 4.5)
  - impaired renal function; or patients with impaired cardiovascular circulation (e.g. renal vascular disease, congestive heart failure, volume depletion, major surgery, sepsis or major haemorrhagic events), since acetylsalicylic acid may further increase the risk of renal impairment and acute renal failure,
  - Caution is required in patients with a history of hypertension and/or heart failure as fluid retention and oedema have been reported in association with BAYER ASPIRIN CARDIO 100 therapy
  - in patients suffering from severe glucose-6-phosphate dehydrogenase (G6PD) deficiency, BAYER ASPIRIN CARDIO 100 may induce haemolysis or haemolytic anaemia. Factors that may increase the risk of haemolysis are e.g. high dosage, fever or acute infections
  - impaired hepatic function;
  - Metamizole and some NSAIDs, such as ibuprofen and naproxen may attenuate acetylsalicylic acid’s inhibitory effect on platelet aggregation. Patients should be advised to talk to their doctor if they are on a BAYER ASPIRIN CARDIO 100 regimen and plan to take metamizole or NSAIDs for pain (see section 4.5).
  - Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported. BAYER ASPIRIN CARDIO 100 should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.

BAYER ASPIRIN CARDIO 100 may precipitate bronchospasm and induce asthma attacks and other hypersensitivity reactions. Risk factors are pre-existing asthma, hay fever, nasal polyps, or chronic respiratory disease. This also applies to patients exhibiting allergic reactions (e.g. cutaneous reactions, itching, urticaria) to other substances.

Due to its inhibitory effect on platelet aggregation which persists for several days after administration, BAYER ASPIRIN CARDIO 100 may lead to an increased bleeding tendency during and after surgical operations (including minor surgeries, e.g. dental extractions).

At low doses, acetylsalicylic acid reduces the excretion of uric acid. This can possibly trigger gout attacks in predisposed patients.

Acetylsalicylic acid containing products should not be used in children and adolescents for viral infections with or without fever without consulting a medical practitioner.

In certain viral illnesses, especially influenzae A, influenzae B and varicella, there is a risk of Reye’s syndrome, a very rare but possibly life-threatening illness requiring immediate medical action. The risk may be increased when BAYER ASPIRIN CARDIO 100 is given concomitantly.
Should persistent vomiting occur with such diseases, this may be a sign of Reye’s syndrome.

4.5 Interaction with other medicines and other forms of interactions.

Contraindicated Interactions

*Methotrexate used at doses of 15 mg/week or more*
Increased haematological toxicity of methotrexate (decreased renal clearance of methotrexate by anti-inflammatory agents in general and displacement of methotrexate from its plasma protein binding by salicylates) (see section 4.3).

Combinations requiring precautions for use

*Methotrexate, used at doses of less than 15 mg/week*
Increased haematological toxicity of methotrexate (decreased renal clearance of methotrexate by anti-inflammatory agents in general and displacement of methotrexate from its plasma protein binding by salicylates).

*Metamizole and NSAIDs*
The concurrent (same day) administration of metamizole and some NSAIDs, such as ibuprofen and naproxen, attenuate the irreversible platelet inhibition induced by acetylsalicylic acid. The clinical relevance of these interactions is not known. Treatment with metamizole and some NSAIDs, such as ibuprofen and naproxen, in patients with increased cardiovascular risk may limit the cardiovascular protection of BAYER ASPIRIN CARDIO 100 (see section 4.4).

*Anticoagulants, thrombolytics/other inhibitors of platelet aggregation/hemostasis*
Increased risk of bleeding.

*Non-steroidal anti-inflammatory medicines with salicylates*
Increased risk of ulcers and gastrointestinal bleeding due to synergistic effect.

*Selective Serotonin Reuptake Inhibitors (SSRIs)*
Increased risk of upper gastrointestinal bleeding due to possibly synergistic effect.

*Digoxin*
Plasma concentrations of digoxin are increased due to a decrease in renal excretion

*Antidiabetics, e.g. insulin, sulphonylureas in combination with acetylsalicylic acid at higher doses*
Increased hypoglycaemic effect at higher doses of acetylsalicylic acid via hypoglycaemic action of acetylsalicylic acid and displacement of sulfonylurea from its plasma protein binding.

*Diuretics in combination with acetylsalicylic acid at higher doses*
Decreased glomerular filtration via decreased renal prostaglandin synthesis.
Systemic glucocorticoids, except hydrocortisone used as replacement therapy in Addison's disease
Decreased blood salicylate levels during corticosteroid treatment and risk of salicylate overdose after this treatment is stopped via increased elimination of salicylates by corticosteroids.
Concurrent use may increase the incidence of gastrointestinal bleeding and ulceration.

Angiotensin converting enzyme inhibitors (ACE) in combination with acetylsalicylic acid at higher doses
Decreased glomerular filtration via inhibition of vasodilator prostaglandins. Furthermore, decreased antihypertensive effect.

Valproic acid
Increased toxicity of valproic acid due to displacement from protein binding sites.

Alcohol
Increased damage to gastro-intestinal mucosa and prolonged bleeding time due to additive effects of acetylsalicylic acid and alcohol

Uricosurics such as benzbromarone, probenecid
Decreased uricosuric effect (competition of renal tubular uric acid elimination).

4.6 Fertility, pregnancy and lactation

Pregnancy
Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/fetal development. During the first and second trimester of pregnancy, medicines containing acetylsalicylic acid are therefore not recommended.
During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to:
- cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension);
- renal dysfunction, which may progress to renal failure with oligo-hydroamniosis;
and the mother and the child, at the end of pregnancy, to:
- possible prolongation of bleeding time, an anti-aggregating effect which may occur even after very low doses
- inhibition of uterine contractions resulting in delayed or prolonged labour
Consequently, BAYER ASPIRIN CARDIO 100 is contraindicated during the third trimester of pregnancy (see section 4.3).

Fertility
Based on the limited published data available, the studies in humans showed no consistent effect of acetylsalicylic acid on impairment of fertility and there is no conclusive evidence from animal studies
Breastfeeding

Salicylates and its metabolites pass into breastmilk in small quantities. Safety is unproven. When regular use of BAYER ASPIRIN CARDIO 100 is indicated, mothers on BAYER ASPIRIN CARDIO 100 should not breastfeed.

4.7 Effects on ability to drive and use machines

BAYER ASPIRIN CARDIO 100 has no or negligible influence on the ability to drive and use machines. However due to side effect such as dizziness, patients should check how they react to BAYER ASPIRIN CARDIO 100 before driving a vehicle or operating machinery.

4.8 Undesirable effects

a) Summary of the safety profile
The listed adverse reactions are based on postmarketing reports with all Aspirin formulations, and clinical trials (CTS) with aspirin as a study medicine. Frequency calculation is based on data from the aspirin arm of the ARRIVE study only.

b) Tabulated summary of adverse reactions
The frequencies of ARs reported with aspirin are summarized in the table below. Frequency groupings are defined according to the following convention: common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) The ARs identified only during post-marketing surveillance, and for which a frequency could not be estimated, are listed under “not known”.

Table 1: Adverse drug reactions (ADRs) reported in ARRIVE* or during post-marketing surveillance in patients treated with BAYER ASPIRIN CARDIO

<table>
<thead>
<tr>
<th>System organ class</th>
<th>Common</th>
<th>Uncommon</th>
<th>Rare</th>
<th>Not known</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and the lymphatic system disorders</td>
<td>Iron deficiency anaemia</td>
<td>Haemorrhagic anaemia</td>
<td>Haemolysis b</td>
<td>Haemolytic anaemia b</td>
</tr>
<tr>
<td>Immune system disorders</td>
<td>Hypersensitivity Medicine hypersensitivity Allergic oedema and angioedema</td>
<td>Anaphylactic reaction</td>
<td>Anaphylactic shock</td>
<td></td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Dizziness</td>
<td>Cerebral and intracranial haemorrhage c</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ear and labyrinth disorders</td>
<td>Tinnitus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td></td>
<td></td>
<td></td>
<td>Cardio-respiratory distress d</td>
</tr>
</tbody>
</table>

CCDS09/072020/SA3.0/062022/
### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions to SAHPRA via the “**6.04 Adverse Drug Reaction Reporting Form**”, found online under SAHPRA’s publications: [https://www.sahpra.org.za/Publications/Index/8](https://www.sahpra.org.za/Publications/Index/8)

### 4.9 Overdose

Salicylate toxicity (> 100 mg/kg/day over 2 days may produce toxicity) may result from chronic, therapeutically acquired, intoxication, and from, potentially life-threatening, acute intoxications (overdose), ranging from accidental ingestions in children to incidental intoxications.
Chronic salicylate poisoning can be insidious as signs and symptoms are non-specific. Mild chronic salicylate intoxication, or salicylism, usually occurs only after repeated use of large doses. Symptoms include dizziness, vertigo, tinnitus, deafness, sweating, nausea and vomiting, headache, and confusion, and may be controlled by reducing the dosage. Tinnitus can occur at plasma concentrations of 150 to 300 micrograms/mL. More serious adverse events occur at concentrations above 300 micrograms/mL.

The principal feature of acute intoxication is severe disturbance of the acid-base balance, which may vary with age and severity of intoxication. The most common presentation for a child is metabolic acidosis. The severity of poisoning cannot be estimated from plasma concentration alone. Absorption of acetylsalicylic acid can be delayed due to reduced gastric emptying, formation of concretions in the stomach, or as a result of ingestion of enteric-coated preparations. Management of acetylsalicylic acid intoxication is determined by its extent, stage and clinical symptoms and according standard poisoning management techniques. Predominant measures should be the accelerated excretion of the drug as well as the restoration of the electrolyte and acid-base metabolism.

Due to the complex pathophysiologic effects of salicylate poisoning, signs and symptoms/investigational findings may include:

<table>
<thead>
<tr>
<th>Signs and Symptoms</th>
<th>Investigational findings</th>
<th>Therapeutic measures</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mild to moderate intoxication</strong></td>
<td></td>
<td>Repeated administration of activated charcoal, forced alkaline diuresis</td>
</tr>
<tr>
<td>Tachypnoea, hyperventilation, respiratory alkalosis</td>
<td>Alkalaemia, alkaluria</td>
<td>Fluid and electrolyte management</td>
</tr>
<tr>
<td>Diaphoresis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea, vomiting</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Moderate to-severe intoxication</strong></td>
<td></td>
<td>Repeated administration of activated charcoal, forced alkaline diuresis, hemodialysis in severe cases</td>
</tr>
<tr>
<td>Respiratory alkalosis with compensatory metabolic acidosis,</td>
<td>Acidaemia, aciduria</td>
<td>Fluid and electrolyte management</td>
</tr>
<tr>
<td>Hyperpyrexia</td>
<td></td>
<td>Fluid and electrolyte management</td>
</tr>
<tr>
<td>Respiratory: ranging from hyperventilation, non-cardiogenic pulmonary edema to respiratory arrest, asphyxiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular: ranging from dysrhythmias, hypotension to cardiovascular arrest</td>
<td>e.g., Blood pressure, ECG alteration</td>
<td></td>
</tr>
<tr>
<td>Fluid and electrolyte loss: dehydration, oliguria to renal failure</td>
<td>e.g., Hypokalaemia, hyperatraemia, hyponatraemia, altered renal function</td>
<td>Fluid and electrolyte management</td>
</tr>
<tr>
<td>Impaired glucose metabolism, ketosis</td>
<td>Hyperglycaemia, hypoglycaemia (especially in children) Increased ketone levels</td>
<td></td>
</tr>
<tr>
<td>Tinnitus, deafness</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Platelet aggregation inhibitors excluding heparin
ATC code- N02BA01

Acetylsalicylic acid inhibits platelet aggregation by blocking thromboxane A2 synthesis in platelets. Its mechanism of action is based on irreversible inhibition of cyclo-oxygenase (COX-1). This inhibitory effect is especially pronounced in platelets because platelets are unable to resynthesize this enzyme.

Platelet aggregation is inhibited for the lifespan of the platelet, 8-10 days.
Acetylsalicylic acid is also thought to have other inhibitory effects on platelets.
Acetylsalicylic acid belongs to the group of acidic nonsteroidal anti-inflammatory drugs with analgesic, antipyretic and anti-inflammatory properties.

5.2 Pharmacokinetic properties

Absorption

Following oral administration, acetylsalicylic acid is well absorbed from the gastro-intestinal tract. During and after absorption acetylsalicylic acid is converted into its main metabolite, salicylic acid. Due to the principle of the acid-resistant formulation of BAYER ASPIRIN CARDIO 100 tablets, acetylsalicylic acid is not released in the stomach but in the alkaline milieu of the intestine. Therefore, Cmax of acetylsalicylic acid is reached 2-7 hours after the administration of the BAYER ASPIRIN CARDIO 100 in comparison to plain tablets.

Simultaneous ingestion of food leads to a delayed but complete absorption of acetylsalicylic acid, implying that its rate of absorption, but not the extent of absorption, is altered by food. Due to the mechanistic relationship between the total plasma exposure of acetylsalicylic acid and its inhibitory effect
on platelet aggregation, the delay of absorption for BAYER ASPIRIN CARDIO is not considered relevant for the chronic therapy with low dose BAYER ASPIRIN CARDIO 100 in order to accomplish adequate inhibition of platelet aggregation. Nevertheless, in order to assure the beneficial gastro-resistance of the formulation, ASPIRIN tablets should be taken preferably (30 minutes or more) before meals, with plenty of liquid (see section 4.2)

**Distribution**

Both acetylsalicylic acid and salicylic acid are extensively bound to plasma proteins and are rapidly distributed throughout the body. Salicylic acid passes into breast milk and crosses the placenta (see section 4.6).

**Metabolism/Biotransformation**

The parent drug acetylsalicylic acid is converted into its main metabolite salicylic acid. The acetyl group of acetylsalicylic acid begins to split off hydrolytically even during passage through the intestinal mucosa but mainly this process takes place in the liver. The main metabolite, salicylic acid is eliminated predominantly by hepatic metabolism. Its metabolites are salicyluric acid, salicylic phenolic glucuronide, salicylacyl glucuronide, gentisic acid, and gentisuric acid.

**Elimination**

The elimination kinetics of salicylic acid is dose-dependent, as metabolism is limited by liver enzyme capacity. The elimination half-life therefore varies from 2 to 3 hours after low doses to up to about 15 hours at high doses. Salicylic acid and its metabolites are excreted mainly via the kidneys.

**5.3 Preclinical safety data**

The preclinical safety profile of acetylsalicylic acid is well documented. In animal studies, salicylates caused kidney damage at high dosages. Acetylsalicylic acid has been extensively studied in vitro and in vivo for mutagenicity; no relevant evidence of a mutagenic potential was found. The same applies to carcinogenicity studies. Salicylates have exhibited teratogenic effects in animal studies and a number of different species. Implantation disorders, embryotoxic and fetotoxic effects and impairment of learning ability in the offspring after prenatal exposure have been described.

**6. PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**

- cellulose,
- maize starch,
- methacrylic acid- ethyl acrylate copolymer,
- tale,
- triethyl citrate,
- sodium lauryl sulphate,
- polysorbate 80
6.2 Incompatibilities
Not Applicable

6.3 Shelf Life
3 years

6.4 Special precautions for storage
Store at or below 30 °C. Keep out of reach of children.

6.5 Nature and contents of container
100 mg tablets packed into PP/Alu or Alu/Alu foil blisters containing 30 tablets in a cardboard carton

6.6 Special precautions for disposal of a used medicine or waste materials derived from such medicine and other handling of the product.

7. HOLDER OF THE CERTIFICATE OF REGISTRATION:
Bayer (Pty) Ltd
Reg. No.: 1968/011192/07
27 Wrench Road
Isando
1609

8. REGISTRATION NUMBERS
31/8/0413

9. DATE OF FIRST AUTHORISATION
09 February 1999

10. DATE OF REVISION OF THE TEXT
30 June 2022

Botswana: (S2) BOT0400713
Mauritius: R9235/02/14
Namibia: NSI04/8/0632
Zimbabwe: (HR) 99/10.5/3596